Abstract
Technological progress in the field of high-throughput technology and the scientific advances in molecular screening have set the ground in the last decades for targeted therapy approaches and precision medicine (PM) in oncology. The utility of molecular profiling in cancer for treatment decision still needs to be proven in well-designed prospective randomized trials, the results of which will be decisive in showing whether or not targeted therapy based on molecular profiling can actually be translated into benefit for patients. For a successful transition toward PM in oncology, several challenges including study designs and biomarkers validation, tissue sampling and tumor heterogeneity, standardization of molecular screening techniques, and bioinformatics in the era of continuous technological progress in addition to financial, regulatory, and ethical aspects need to be addressed.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call